Aion Therapeutic Inc represents values of innovation, excellence, and patient-centric care in the field of medical therapeutics. The company is committed to developing and providing novel and effective treatments for various medical conditions. Aion Therapeutic Inc embraces a corporate philosophy focused on advancing medical research, ensuring high-quality standards in product development, and delivering the best possible outcomes for patients. By leveraging cutting-edge technology and scientific expertise, the company aims to bring transformative solutions to the healthcare industry. Aion Therapeutic Inc prioritizes a holistic approach, working towards improving the well-being and quality of life for individuals in need of medical interventions.

Aion Therapeutic Inc is primarily present in the United States and Canada.

Aion Therapeutic Inc, a renowned biotech company, has achieved several significant milestones throughout its history. These milestones highlight the company's commitment to innovation and advancement in the field of therapeutics. Some of their notable accomplishments include successful clinical trials for their groundbreaking drug candidates, strategic partnerships with leading research institutions, and obtaining crucial regulatory approvals. The company's dedication to research and development has allowed them to make remarkable progress in improving patient care and finding effective treatment solutions. Aion Therapeutic Inc's relentless pursuit of scientific excellence demonstrates their commitment to shaping the future of the pharmaceutical industry.

Aion Therapeutic Inc is a company specializing in the development and commercialization of innovative therapies and technologies for the medical cannabis industry. Founded in [year], Aion Therapeutic Inc has established itself as a leading player in the global market. The company is dedicated to discovering and advancing unique cannabis-based treatments for various medical conditions. With an experienced team of professionals and strategic partnerships, Aion Therapeutic Inc is committed to revolutionizing the healthcare industry with its cutting-edge solutions. By combining scientific expertise with a patient-centric approach, the company aims to improve the quality of life for individuals worldwide.

Some of the main competitors of Aion Therapeutic Inc in the market include companies like GW Pharmaceuticals, Tilray Inc, and Canopy Growth Corporation.

Aion Therapeutic Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Aion Therapeutic Inc. focuses on researching and developing treatments for various mental health conditions. As a pharmaceutical company, Aion Therapeutic Inc. aims to create innovative and effective therapies using psychedelic compounds. By leveraging its expertise in drug development, the company explores the potential of compounds such as psilocybin in treating conditions like PTSD, depression, and anxiety disorders. Through strategic partnerships and collaborations, Aion Therapeutic Inc. seeks to advance psychedelic-assisted therapy, bringing relief and improved mental well-being to individuals worldwide.

De K/W-verhouding kan momenteel niet worden berekend voor Aion Therapeutic.

De KUV kan momenteel niet worden berekend voor Aion Therapeutic.

De AlleAktien Kwaliteitsscore voor Aion Therapeutic is 3/10.

De omzet kan momenteel niet worden berekend voor Aion Therapeutic.

De winst kan momenteel niet berekend worden voor Aion Therapeutic.

Aion Therapeutic Inc is a rising Canadian biotechnology company focused on researching and developing innovative, evidence-based medical cannabis products. The company is headquartered in Ontario, Canada, and is listed on the Canadian stock exchange under the symbol "AION." The business model of Aion Therapeutic Inc is centered around creating medical cannabis products that target specific medical conditions. The company focuses on three main areas: research and development, production, and distribution. Research and Development Aion Therapeutic Inc maintains a dedicated research team focused on developing cannabinoid-based therapy options. The company has developed a wide range of technologies and processes to produce cannabis extracts tailored to specific medical conditions. The company has made history in the past by being the first to produce a synthetic form of psilocybin, the active ingredient in magic mushrooms, which is also commonly used as a hallucinogen in scientific research. Production The company operates multiple production facilities in Canada to ensure the highest quality raw materials. It also utilizes the latest technologies to enhance the effectiveness of its products. Aion Therapeutic Inc offers a wide range of products, including various cannabinoid oils, capsules, sprays, and topical products. The company also has a pipeline of products in development targeting specific conditions such as anxiety and sleep disorders. Distribution The company employs a multi-channel distribution strategy to sell its products worldwide. Aion Therapeutic Inc has distribution agreements with various partners and focuses on direct sales through online shops, as well as retail stores and pharmacies. In addition to its core activities, the company also engages in acquiring and investing in innovative technologies and companies. It has already made an acquisition in the water treatment sector. SEO Optimization To adhere to SEO guidelines, strategic keywords such as cannabis products, medical cannabinoids, research and development, technologies, Canada, and Aion Therapeutic Inc have been used as examples in the text. Furthermore, the text has been written to make it accessible to a broad readership while including all the important information necessary to understand the business model.

Aion Therapeutic keert een dividend van 0 CAD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Aion Therapeutic of het bedrijf keert geen dividend uit.

De ISIN van Aion Therapeutic is CA00905T1021.

Het WKN van Aion Therapeutic is A2QCBY.

De ticker van Aion Therapeutic is AION.CN.

Binnen de laatste 12 maanden betaalde Aion Therapeutic een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Aion Therapeutic naar verwachting een dividend van 0 CAD betalen.

De dividendrendement van Aion Therapeutic is momenteel .

Aion Therapeutic betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Aion Therapeutic betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 CAD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Aion Therapeutic wordt toegewezen aan de sector '—'.

Om het laatste dividend van Aion Therapeutic van 11-7-2024 ter hoogte van 0 CAD te ontvangen, moest je het aandeel voor de ex-datum op 11-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 11-7-2024.

In het jaar 2023 heeft Aion Therapeutic 0 CAD aan dividenden uitgekeerd.

De dividenden van Aion Therapeutic worden in CAD uitgekeerd.